Stocks
Ionis Pharmaceuticals Financial Statements (IONS) |
||||||||||
| Ionis Pharmaceuticalssmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 02.03.2020 | 24.02.2021 | 25.02.2022 | 22.02.2023 | 21.02.2024 | 21.02.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 1 123 | 729.0 | 810.0 | 587.0 | 787.6 | 787.5 | |||
| Operating Income, bln rub | 366.0 | -172.0 | -30.0 | -411.0 | -353.7 | -354.1 | ||||
| EBITDA, bln rub | ? | 366.0 | -172.0 | -21.0 | -561.0 | -322.8 | -280.7 | |||
| Net profit, bln rub | ? | 294.0 | -487.0 | -29.0 | -270.0 | -366.3 | -365.3 | |||
| OCF, bln rub | ? | 345.7 | 35.9 | 30.8 | -274.4 | -307.5 | -307.5 | |||
| CAPEX, bln rub | ? | 36.3 | 41.0 | 17.9 | 20.1 | 28.0 | 28.9 | |||
| FCF, bln rub | ? | 309.4 | -5.16 | 12.9 | -294.5 | -335.5 | -334.7 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 753.0 | 889.0 | 829.0 | 984.0 | 1 132 | 1 133 | ||||
| Cost of production, bln rub | 4.00 | 12.0 | 11.0 | 14.0 | 9.13 | 9.06 | ||||
| R&D, bln rub | 466.0 | 535.0 | 643.0 | 833.0 | 899.6 | 899.6 | ||||
| Interest expenses, bln rub | 49.0 | 45.0 | 4.30 | 8.12 | 75.6 | 72.8 | ||||
| Assets, bln rub | 3 233 | 2 390 | 2 612 | 2 534 | 2 990 | 2 990 | ||||
| Net Assets, bln rub | ? | 1 471 | 843.0 | 772.0 | 573.0 | 386.7 | 386.7 | |||
| Debt, bln rub | 710.0 | 749.0 | 1 161 | 1 345 | 1 454 | 1 454 | ||||
| Cash, bln rub | 2 500 | 1 892 | 2 115 | 1 987 | 2 331 | 2 331 | ||||
| Net debt, bln rub | -1 790 | -1 143 | -954.0 | -642.0 | -877.7 | -877.7 | ||||
| Ordinary share price, rub | 60.4 | 56.5 | 30.4 | 37.8 | 50.6 | 43.7 | ||||
| Number of ordinary shares, mln | 140.0 | 139.6 | 141.0 | 141.8 | 143.2 | 144.0 | ||||
| Market cap, bln rub | 8 457 | 7 894 | 4 291 | 5 358 | 7 244 | 6 297 | ||||
| EV, bln rub | ? | 6 667 | 6 751 | 3 337 | 4 716 | 6 366 | 5 419 | |||
| Book value, bln rub | 1 445 | 815 | 743 | 573 | 387 | 387 | ||||
| EPS, rub | ? | 2.10 | -3.49 | -0.21 | -1.90 | -2.56 | -2.54 | |||
| FCF/share, rub | 2.21 | -0.04 | 0.09 | -2.08 | -2.34 | -2.32 | ||||
| BV/share, rub | 10.3 | 5.84 | 5.27 | 4.04 | 2.70 | 2.69 | ||||
| EBITDA margin, % | ? | 32.6% | -23.6% | -2.59% | -95.6% | -41.0% | -35.6% | |||
| Net margin, % | ? | 26.2% | -66.8% | -3.58% | -46.0% | -46.5% | -46.4% | |||
| FCF yield, % | ? | 3.66% | -0.07% | 0.30% | -5.50% | -4.63% | -5.32% | |||
| ROE, % | ? | 20.0% | -57.8% | -3.76% | -47.1% | -94.7% | -94.5% | |||
| ROA, % | ? | 9.09% | -20.4% | -1.11% | -10.7% | -12.3% | -12.2% | |||
| P/E | ? | 28.8 | -16.2 | -148.0 | -19.8 | -19.8 | -17.2 | |||
| P/FCF | 27.3 | -1 531 | 332.7 | -18.2 | -21.6 | -18.8 | ||||
| P/S | ? | 7.53 | 10.8 | 5.30 | 9.13 | 9.20 | 8.00 | |||
| P/BV | ? | 5.85 | 9.68 | 5.78 | 9.35 | 18.7 | 16.3 | |||
| EV/EBITDA | ? | 18.2 | -39.2 | -158.9 | -8.41 | -19.7 | -19.3 | |||
| Debt/EBITDA | -4.89 | 6.65 | 45.4 | 1.14 | 2.72 | 3.13 | ||||
| R&D/CAPEX, % | 1 284% | 1 303% | 3 592% | 4 144% | 3 212% | 3 117% | ||||
| CAPEX/Revenue, % | 3.23% | 5.63% | 2.21% | 3.42% | 3.56% | 3.66% | ||||
| Ionis Pharmaceuticals shareholders | ||||||||||
